Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.70, $0.05 better than the analyst estimate of $0.65. Revenue for the quarter came in at $179.5 million versus the consensus estimate of $182.29 million.

GUIDANCE:

Pacira Pharma sees FY2025 revenue of $725-735 million, versus the consensus of $737.2 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.